MedTrace Logo

Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success

NCT05702879 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 240

Last updated 2023-12-06

No results posted yet for this study

Summary

The primary goal of the study is to develop an early (within 4 weeks) combined microbiota/metabolic signature predicting clinical response upon anti-inflammatory treatment in UC patients.

Conditions

Interventions

DRUG

Ozanimod

Start of standard therapy

DRUG

TNF Inhibitor

Start of standard therapy

DRUG

Steroids

Start of standard therapy

DRUG

Vedolizumab

Start of standard therapy

DRUG

Ustekinumab

Start of standard therapy

Sponsors & Collaborators

Principal Investigators

  • Benjamin Misselwitz, Prof. · Insel Gruppe AG, University Hospital Bern

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-06
Primary Completion
2025-01-31
Completion
2025-01-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05702879 on ClinicalTrials.gov